for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aerpio Pharmaceuticals Inc

ARPO.OQ

Latest Trade

0.72USD

Change

0.02(+2.86%)

Volume

11,386

Today's Range

0.67

 - 

0.72

52 Week Range

0.61

 - 

4.25

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.70
Open
0.70
Volume
11,386
3M AVG Volume
1.77
Today's High
0.72
Today's Low
0.67
52 Week High
4.25
52 Week Low
0.61
Shares Out (MIL)
40.59
Market Cap (MIL)
28.41
Forward P/E
-1.03
Dividend (Yield %)
--

Latest Developments

More

Aerpio Q2 Loss Per Share $0.14

Aerpio Pharmaceuticals Receives Non-Compliance Letter From Nasdaq

Aerpio Pharmaceuticals Q1 Loss Per Share $0.21

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aerpio Pharmaceuticals Inc

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing treatments for ocular disease. Its lead product candidate is AKB-9778. Its other two pipeline programs include AKB-4924 and ARP-1536. AKB-9778 is a small molecule activator of the Tie-2 pathway, which is being developed for the treatment of diabetic retinopathy (DR). AKB-4924 is a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha), which is being developed for the treatment of inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody directed at the same target as AKB-9778. ARP-1536 binds the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibiting its ability to interact with Tie-2. As of April 14, 2017, the Company had completed a Phase II trial of AKB-9778 in 144 patients with diabetic macular edema. As of April 14, 2017, the Company had completed Phase Ia clinical trial in healthy volunteers for AKB-4924.

Industry

Biotechnology & Drugs

Contact Info

9987 Carver Rd

+1.513.9851920

https://aerpio.com/

Key Stats

2.50 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019(E)

0.0K
EPS (USD)

2018

-0.310

2019(E)

-0.677
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.51
Price To Book (MRQ)
0.62
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-23.76
Return on Equity (TTM)
-18.73

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up